- 主题
- 395
- 您的身份
- 病友
- 就诊医院
- 北京协和
- 病理报告
- 滤泡性淋巴瘤1-2级
- 目前状态
- 康复10-20年
参加活动:0 次 组织活动:0 次
您的身份病友
病理报告滤泡性淋巴瘤1-2级
就诊医院北京协和
目前状态康复10-20年
最后登录2025-12-21
  
|
发表于 2025-9-19 08:35:40
|
显示全部楼层
来自: 中国北京
Viral Reactivation
Hepatitis B virus (HBV):
• Anti-CD20 mAb-based chemoimmunotherapy is associated with
risk of HBV reactivation. Hepatitis B surface antigen (HBsAg) and
hepatitis B core antibody (HBcAb) testing for all patients receiving
anti-CD20 mAb therapy
Quantitative hepatitis B viral load by PCR and surface antibody
only if one of the screening tests is positive
• Note: Patients receiving IV immunoglobulin (IVIG) may be HBcAb
positive as a consequence of IVIG therapy.
• Prophylactic antiviral therapy with entecavir is recommended for
any patient who is HBsAg-positive and receiving anti-lymphoma
therapy. If there is active disease (PCR+), it is considered treatment/
management and not prophylactic therapy. In cases of HBcAb
positivity, prophylactic antiviral therapy is preferred; however, if
there is a concurrent high-level hepatitis B surface antibody, these
patients may be monitored with serial hepatitis B viral load.
Entecavir is preferredb
Avoid lamivudine due to risks of resistance development.
Other antivirals including adefovir, telbivudine, and tenofovir are
proven active treatments and are acceptable alternatives.
Monitor hepatitis B viral load with PCR monthly through treatment
and every 3 months thereafter.
◊ If viral load is consistently undetectable, treatment is considered
prophylactic.
◊ If viral load fails to drop or previously undetectable PCR
becomes positive, consult hepatologist and discontinue anti
CD20 mAb therapy.
Maintain prophylaxis up to 12 months after oncologic treatment ends
◊ Consult with hepatologist for duration of therapy in patient with
active HBV.
这是NCCN指南B细胞淋巴瘤2025版中关于乙肝再激活预防的部分,基本上和我上面说的差不多,核心抗体阳性的患者推荐做预防,但如果抗体滴度较高,也可不做预防,即使做预防,最多在肿瘤治疗结束后再持续12个月,绝不需要吃一辈子恩替卡韦,除非表面抗原阳性。
|
|